Biochemical Markers of Bone Metabolism

References

• Delmas P D. Biochemical markers of bone turnover in osteoporosis. Osteoporosis: etiology, diagnostics and management, B L Riggs, L J Melton, III. (in press)Raven Press, New York 1988; 297–316
   Google Scholar
• Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocrine Rev 1988; 9: 427–49
   Web of Science ®Google Scholar
• Azrla M. The value of biomarkers in detecting alterations in bone metabolism. Calcif Tissue Int 1989; 45: 7–11
   PubMed Web of Science ®Google Scholar
• Deftos L J. Bone protein and peptide assays in the diagnosis and management of skeletal disease. Clin Chem 1991; 37: 1143–8
   PubMed Web of Science ®Google Scholar
• Eyre D. Editorial: New biomarkers of bone resorption. J Clin Endocrinol Metab 1992; 74: 470A–C
   PubMed Web of Science ®Google Scholar
• Seibel M J, Robins S P, Bilezikian J P. Urinary pyridinium crosslinks of collagen. Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3: 263–70
   PubMed Web of Science ®Google Scholar
• Risteli L, Risteli J. Carboxyterminal propeptide of type I procollagen. A new direct indicator of bone matrix formation. Ital J Mineral Electrolyte Metab 1992; 6: 1–6
   Google Scholar
• Stein G S, Lian J B, Owen T A. Relationship of cell growth to the regulation of tissue‐specific gene expression during osteoblast differentiation. FASEB J 1990; 4: 3111–23
   PubMed Web of Science ®Google Scholar
• Taubman M B, Goldberg B, Sherr C J. Radioimmunoassay for human procollagen. Science 1974; 186: 1115–7
   PubMed Web of Science ®Google Scholar
• Melkko J, Nieml S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328–32
   PubMed Web of Science ®Google Scholar
• Parfitt A M, Simon L S, Vlllanueva A R, Krane S M. Procollagen type I carboxy‐terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2: 427–36
   PubMed Web of Science ®Google Scholar
• Coen G, Mazzaferro S, Ballanti P, et al. Procollagen type I C‐terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 1992; 12: 246–51
   PubMed Web of Science ®Google Scholar
• Eriksen E F, Charles P, Melsen F, Mosekilde L, Risteli L, Ristell J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry. J Sone Miner Res 1993; 8: 127–32
   PubMed Web of Science ®Google Scholar
• Trivedl P, Risteli J, Risteli L, Hindmarsh P C, Brook C GD, Mowat A P. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 1991; 30: 276–80
   PubMed Web of Science ®Google Scholar
• Hyams J S, Moore R E, Leichtner A M, Carey D E, Goldberg B D. Longitudinal assessment of type I procollagen in children with inflammatory bowel disease subjected to surgery. J Pediatr Gastroenterol Nutr 1989; 8: 68–74
   PubMed Web of Science ®Google Scholar
• Smedsrød B, Melkko J, Risteli L, Risteli J. Circulating carboxyterminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345–50
   PubMed Web of Science ®Google Scholar
• Fischer L W, Robey P G, Tuross N, et al. The Mr 24000 phosphoprotein from developing bone is the NH2‐terminal propeptide of the α1 chain of type I collagen. J Biol Chem 1987; 262: 13457–63
   PubMed Web of Science ®Google Scholar
• Jukkola A, Risteli L, Melkko J, Risteli J. Procollagen synthesis and extracellular matrix deposition in MG‐63 osteosarcoma cells. J Bone Miner Res 1993, (in press)
   PubMed Web of Science ®Google Scholar
• Rasmussen H B, Teisner B, Bangsgaard‐Petersen F, Yde‐Andersen E, Kassem M. Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum, and serum from patients with chronic renal failure. Nephrol Dial Transplant 1992; 7: 902–7
   PubMed Web of Science ®Google Scholar
• Teisner B, Rasmussen H B, Højrup P, Yde‐Andersen E, Skjødt K. Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the α1 chain of human procollagen type I. APMIS 1992; 100: 1106–14
   PubMed Web of Science ®Google Scholar
• Rasmussen H B, Teisner B, Gram J, Brixen K, Yde‐Andersen E, Bollerslev J. Serum levels of fetal antigen 2 in hyperthyroidism and primary hyperparathyroidism. APMIS 1992; 100: 894–900
   PubMed Web of Science ®Google Scholar
• Ebeling P R, Peterson J M, Riggs B L. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243–50
   PubMed Web of Science ®Google Scholar
• Brixen K, Nielsen H K, Eriksen E F, Charles P, Mosekilde L. Efficacy of wheat germ lectin‐precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla‐protein. Calcif Tissue Int 1989; 44: 93–8
   PubMed Web of Science ®Google Scholar
• Schiele F, Henny J, Hitz J, Petltclerc C, Gueguen R, Siest G. Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem 1983; 29: 634–41
   PubMed Web of Science ®Google Scholar
• Gundberg C, Grant F D, Conlin P R, et al. Acute changes in serum osteocalcin during induced hypocalcemia in humans. J Clin Endocrinol Metab 1991; 72: 438–43
   PubMed Web of Science ®Google Scholar
• Taylor A K, Linkhart S, Mohan S, Christenson R A, Singer F R, Baylink D J. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 1990; 70: 467–72
   PubMed Web of Science ®Google Scholar
• Delmas P D, Christiansen C, Mann K G, Price P A. Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res 1990; 5: 5–11
   PubMed Web of Science ®Google Scholar
• Plantalech L, Guillaumont M, Vergnaud P, Leclercq M, Delmas P D. Impairment of gamma carboxylation of circulating osteocalcin (bone Gla protein) in elderly women. J Bone Miner Res 1991; 6: 1211–6
   PubMed Web of Science ®Google Scholar
• Kraenzlin M E, Lau K ‐HW, Liang L, et al. Development of an immunoassay for human serum osteoclastic tartrate‐resistant acid phosphatase. J Clin Endocrinol Metab 1990; 71: 442–51
   PubMed Web of Science ®Google Scholar
• Hanson D A, Weis M AE, Bollen A ‐M, Maslan S L, Singer F R, Eyre D R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross‐linked N‐telopeptides in urine. J Bone Miner Res 1992; 7: 1251–8
   PubMed Web of Science ®Google Scholar
• Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross‐linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635–40
   PubMed Web of Science ®Google Scholar
• Hartmann D J, Trinchet J ‐C, Ricard‐Blum S, Beaugrand M, Callard P, Ville G. Radioimmunoassay of type I collagen that mainly detects degradation products in serum: application to patients with liver diseases. Clin Chem 1990; 36: 421–6
   PubMed Web of Science ®Google Scholar
• Kivirikko Kl. Urinary excretion of hydroxyproline in health and disease. Int Rev Connect Tissue Res 1970; 5: 93–163
   PubMedGoogle Scholar
• Robins S P. Turnover and crosslinking of collagen. Collagen in health and disease, J B Weiss, M IV Jayson. Churchill Livingstone, Edinburgh 1982; 160–78
   Google Scholar
• James I, Crowley C, Perrett D. Assay of pyridinium crosslinks in serum using narrow‐bone ion‐paired reversed‐phase high‐performance liquid chromatography. J Chromatogr 1993; 612: 41–8
   PubMed Web of Science ®Google Scholar
• Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross‐linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Brit J Cancer 1992; 66: 337–41
   PubMed Web of Science ®Google Scholar
• Kylmälä T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993; 29A: 821–5
   PubMed Web of Science ®Google Scholar
• Morrison N A, Yeoman R, Kelly P J, Eisman J A. Contribution of trans‐acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 1992; 89: 6665–9
   PubMed Web of Science ®Google Scholar
• Parfitt A M. Commentary. Growth hormone and adult bone remodelling. Clin Endocrinol 1991; 35: 467–70
   PubMed Web of Science ®Google Scholar
• Jensen L T, Olesen H P, Risteli J, Lorenzen I. External thoracic duct‐venous shunt in conscious pigs for long‐term studies of connective tissue metabolites in lymph. Lab Anim Sci 1990; 40: 620–4
   PubMedGoogle Scholar